Hims & Hers started prescribing compounded semaglutide, the active ingredient in Wegovy, a year ago. CEO Andrew Dudum said he believes the company’s partnership with Novo Nordisk will serve as ...

Novo Nordisk appears to be letting compounded GLP-1 bygones ... of selling compounded versions of semaglutide, the drug better known as Novo’s blockbusters Wegovy and Ozempic.

It includes Wegovy and Zepbound medications as well as its latest offering, Noom GLP-1Rx, which features compounded semaglutide. How it works: Like other services on our list, Noom Med provides ...

When the FDA declared the shortage resolved for semaglutide, the main pharmaceutical ingredient in Wegovy and Ozempic, the agency gave 503B facilities until May 22 to stop making compounded versions.

Blockbuster obesity and diabetes drugs — such as Wegovy, Ozempic, and Mounjaro — are no longer deemed by regulators to be in shortage, so compounding pharmacies and the telehealth companies ...

Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's diabetes drug Ozempic and Wegovy, in May of 2024. The company has largely had to stop offering the ...